BIOT BIOT
Company Profile ↓Company Overview
BIOT (BIOT) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.10.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Nov 2024 Revenue of $2.76M (-19.6% YoY); net profit $74.66K.
- Trailing 12 Months Year-on-year growth — revenue -19.6%, earnings -86.3%.
- 5-Year Trend Long-term compounding — revenue CAGR -19.6%, profit CAGR -86.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -19.58% |
| 1 Year: | -19.58% |
Compounded Profit Growth
| 5 Years: | -86.30% |
| 1 Year: | -86.30% |
Stock Price Performance
| 1 Year: | -97.23% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -19.6% CAGR over 5 years.
- Earnings shrank at -86.3% CAGR over 5 years.
- Trading 97.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Nov 2023 | Nov 2024 |
|---|---|---|
| Revenue | 3.43M | 2.76M |
| Cost of Revenue | 456.05K | 761.92K |
| Gross Profit | 2.98M | 2.00M |
| Operating Expenses | 2.58M | 2.07M |
| Operating Income | 398.89K | -67.91K |
| EBITDA | 817.00K | 366.89K |
| Interest Expense | 8.47K | 3.56K |
| Pretax Income | 591.83K | 126.46K |
| Tax Provision | 46.95K | 51.80K |
| Net Income | 544.88K | 74.66K |
| Diluted EPS | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Nov 2023 | Nov 2024 |
|---|---|---|
| Total Assets | 3.42M | 3.11M |
| Current Assets | 1.90M | 1.81M |
| Cash & Equivalents | 240.38K | 512.45K |
| Inventory | 473.22K | 368.76K |
| Receivables | 349.68K | 420.39K |
| Total Liabilities | 1.11M | 767.89K |
| Current Liabilities | 863.86K | 662.60K |
| Long Term Debt | - | - |
| Total Debt | 510.73K | 233.26K |
| Total Equity | 2.31M | 2.34M |
| Shares Outstanding | - | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Nov 2023 | Nov 2024 |
|---|---|---|
| Operating Cash Flow | -977.79K | 589.72K |
| Investing Cash Flow | -70.31K | -26.79K |
| Financing Cash Flow | 18.78K | -269.39K |
| Capital Expenditure | -70.31K | -26.79K |
| Free Cash Flow | -1.05M | 562.94K |
| Net Change in Cash | -1.03M | 293.55K |
Ratios (Annual)
Figures in %.
| Metric | Nov 2023 | Nov 2024 |
|---|---|---|
| Gross Margin % | 86.7% | 72.4% |
| Operating Margin % | 11.6% | -2.5% |
| Net Margin % | 15.9% | 2.7% |
| ROE % | 23.6% | 3.2% |
| ROCE % | 15.6% | -2.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BIOT
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBDT0NQVmVpNk9HWERMR0xEUDZoZkdac21zSGJFUWJfZE5rcVU1RUY4MDZ1clR3ZTg4OFNZbkRYVnVtZDVudi1mX1ROUGk2UkNt?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Diluted shares outstanding of Instinct Bio Technical Company Holdings Inc. – NASDAQ:BIOT - TradingView
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQLU9lVWxWS00tLXVqb3BnanFxOXVRak1OcXJVVnpJdnpBaVgtZGlPVDJqa1dJdUZZTFhJX1VlQndhZURXLTZMWHdncURQNnVtWFo5VzBaMTVVdmdDbXpjZVdtaWZkdS1GamJDME5SZVE1Si1MUkFWdkFWWDJsOVRqQ3l4UnBCc3pzTjVidk…
Instinct Bio Completes Business Combination with Relativity - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMiuAJBVV95cUxQOXFDUDByOHpFNGtHWjdVQU1zSjg5OE8wUUhDZzVMZHFiWWxxZG5CckZwREowQ2VnVHhneXd2NUN6Y0hGOE1tYUdpd2dOSGNoZlhNVmFDR2Z6aTg0VklsMWdJYXpmeGVXTXo5dUVuazBUb085bnFscFZUeFZxWkxlWExsMzBYdFRiQWdEOG…
Instinct Bio's BIOT Shares Expected to Begin Nasdaq Trading July 24 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPakVQN2w3MGQ3TU1iSlkwVF8xaTl2VFREbWd5RXAySi0zeUtqZVUxOUhpcFVaR1RGWU5INjkxWU10Wk50eEpTOFpfUTFROHFTeDVteUtHUzgyNVVoYkNoWXJ3Vm9DOWMzYU9MejVuRjZGN2VTQmpzcFlMOVJ4XzN3Wnd5VFpKbXZKMlU4VU…
Market Movers | Winners: CNET, OPK, ITRI | Losers: YYAI, BIOT, SPWR - Trefis
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQUU1YZUtKNy12MkdDenVBelY1aFBvYk53LWdNVW9KNGhNblNjVTV5MFNoQjFJZWNRM3RPT2xsa1lDaE5uOUluV0tXM0VZbUJNVHhObFBsZkEzVFBremxVWUhrZDdYdUZyTlRkV2RmOFlWWXd0dHplSVIwMnFFMEVoRUV3Qlh3NFJ3d1dhb1…
Instinct Bio Stock Slides After Hours: Here's What is Going on With BIOT - Benzinga
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOaFl5WG43Q0s1WWRHamVYa0xEZThNZEk2am1DQzM1Y1ZHX0VIbk40NUhzMmNrZnk2czY4UFdkTThtZTNURGZ1eUhPWWY1Qzl4dldPUEtCS256bDJNR0JrU2dNRkJUR3ZkeWE1SXdMRWFIRVZqaHY1bVhkVDVDVzg3c1hpakJ4cmZaNnlzWG…
BIOT — Frequently Asked Questions
What is the current share price of BIOT?
As of 2026-08-05 17:25 PDT, BIOT trades at $0.43 on NASDAQ/NYSE. Its 52-week range is $0.43 to $15.50.
What is the return on equity (ROE) of BIOT?
BIOT has a return on equity (ROE) of 3.19%. Its return on capital employed (ROCE) is 5.32%.
Is BIOT a good stock to buy?
This page provides a data-driven analysis of BIOT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.